Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Change in Acquisitions & Divestments: 2009-2025

Historic Change in Acquisitions & Divestments for Cytokinetics (CYTK) over the last 17 years, with Sep 2025 value amounting to $273.8 million.

  • Cytokinetics' Change in Acquisitions & Divestments rose 61.03% to $273.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 61.17%. This contributed to the annual value of $744.2 million for FY2024, which is 14.55% down from last year.
  • As of Q3 2025, Cytokinetics' Change in Acquisitions & Divestments stood at $273.8 million, which was down 0.06% from $274.0 million recorded in Q2 2025.
  • Over the past 5 years, Cytokinetics' Change in Acquisitions & Divestments peaked at $284.4 million during Q2 2023, and registered a low of $64.2 million during Q1 2021.
  • For the 3-year period, Cytokinetics' Change in Acquisitions & Divestments averaged around $221.7 million, with its median value being $233.3 million (2024).
  • As far as peak fluctuations go, Cytokinetics' Change in Acquisitions & Divestments skyrocketed by 219.43% in 2021, and later crashed by 41.78% in 2024.
  • Over the past 5 years, Cytokinetics' Change in Acquisitions & Divestments (Quarterly) stood at $96.7 million in 2021, then skyrocketed by 63.04% to $157.6 million in 2022, then fell by 8.15% to $144.8 million in 2023, then soared by 61.12% to $233.3 million in 2024, then surged by 61.03% to $273.8 million in 2025.
  • Its last three reported values are $273.8 million in Q3 2025, $274.0 million for Q2 2025, and $275.7 million during Q1 2025.